In order to evaluate potential heterogeneity of effects of CINA and RIO, we assessed the impact of these agents on platelet sGC signalling across the entire spectrum of baseline sGC responsiveness by including not only a normal control group but also patient comparator groups consisting of patients with different cardiovascular disease states, who were anticipated to have a lesser degree of NO resistance than CAS patients [10,15]. The gene discussed is SGCB; the disease is cardiovascular disorder.